Highlights Syntara Limited

Equities

SNT

AU0000312480

End-of-day quote Australian S.E. Other stock markets 23:00:00 09/05/2024 BST			5-day change	1st Jan Change
0.018 ^AUD	+12.50%		+20.00%	-10.00%

04-30	Transcript : Syntara Limited, Q3 2024 Earnings Call, Apr 30, 2024
04-10	Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment	04-10	MT
Syntara Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-29	CI
Syntara Receives AU$5.2 Million R&D Tax Rebate	12-05	MT
Pharmaxis Ltd Reports Earnings Results for the First Quarter Ended September 30, 2023	31/10/23	CI
Pharmaxis Sells Mannitol Business; Shares Fall 3%	19/10/23	MT
Arna Pharma Pty Ltd completed the acquisition of Mannitol respiratory business of Pharmaxis.	18/10/23	CI
Pharmaxis to Change Name Amid Restructure, Appoints Chair	03/10/23	MT
Arna Pharma Pty Ltd entered into definitive agreement to acquire Mannitol respiratory business of Pharmaxis.	02/10/23	CI
Pharmaxis Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	28/08/23	CI
Pharmaxis Secures US FDA Guidance to Expand Myelofibrosis Trial	12/04/23	MT
Pharmaxis Ltd Announces Results from Combination of PXS-5505 and Standard of Care Demonstrates A Strong Ration for Treatment of Red Blood Cells	22/03/23	CI
Pharmaxis Shrinks Fiscal H1 Loss	10/02/23	MT
Pharmaxis Ltd Reports Earnings Results for the Half Year Ended December 31, 2022	10/02/23	CI
Pharmaxis Receives AU$5 Million R&D Tax Rebate	09/01/23	MT
Pharmaxis Announces Clinical Trial of Its Topical Anti Scarring Drug PXS6302 Complete Recruitment with the Last of the 42 Patients	20/12/22	CI
Pharmaxis Ltd Reports Earnings Results for the First Quarter Ended September 30, 2022	31/10/22	CI
Pharmaxis Ltd Announces Positive Interim Data from Myelofibrosis Trial	18/10/22	CI
Pharmaxis Ltd Releases Promising Interim Data from Skin Scarring Study	25/09/22	CI
Pharmaxis Ltd Updates on Phase 2 Study of the Pharmaxis Drug Discovery PXS4728	31/08/22	CI
Aptar Pharma Pays Pharmaxis USD 5 Million to Acquire Orbital Technology	04/08/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Syntara Limited

Equities

SNT

AU0000312480

Highlights

Filters